+

WO2010074992A3 - Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques - Google Patents

Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques Download PDF

Info

Publication number
WO2010074992A3
WO2010074992A3 PCT/US2009/067552 US2009067552W WO2010074992A3 WO 2010074992 A3 WO2010074992 A3 WO 2010074992A3 US 2009067552 W US2009067552 W US 2009067552W WO 2010074992 A3 WO2010074992 A3 WO 2010074992A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
controlled release
sensory cell
compositions
Prior art date
Application number
PCT/US2009/067552
Other languages
English (en)
Other versions
WO2010074992A2 (fr
Inventor
Jay Lichter
Benedikt Vollrath
Andrew M. Trammel
Sergio G. DURÓN
Fabrice Piu
Luis A. Dellamary
Qiang Ye
Carl Lebel
Michael Christopher Scaife
Jeffrey P. Harris
Original Assignee
Otonomy, Inc.
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0907070A external-priority patent/GB2461962B/en
Priority claimed from US12/504,553 external-priority patent/US8496957B2/en
Application filed by Otonomy, Inc., The Regents Of The University Of California filed Critical Otonomy, Inc.
Priority to EP09835529.0A priority Critical patent/EP2299976A4/fr
Priority to AU2009330458A priority patent/AU2009330458B2/en
Priority to CN2009801305625A priority patent/CN102112111A/zh
Priority to CA2732686A priority patent/CA2732686C/fr
Priority to JP2011542272A priority patent/JP6013736B2/ja
Publication of WO2010074992A2 publication Critical patent/WO2010074992A2/fr
Publication of WO2010074992A3 publication Critical patent/WO2010074992A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions et des procédés de traitement de troubles ou d'états otiques avec des compositions ou des formulations d'agent modulant les cellules sensorielles auriculaires administrées localement à un individu souffrant d'une maladie ou d'un état otique, par application directe de ces compositions ou formulations sur la ou les structures auriculaires ciblées ou par perfusion dans ces structures.
PCT/US2009/067552 2008-12-22 2009-12-10 Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques WO2010074992A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP09835529.0A EP2299976A4 (fr) 2008-12-22 2009-12-10 Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques
AU2009330458A AU2009330458B2 (en) 2008-12-22 2009-12-10 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN2009801305625A CN102112111A (zh) 2008-12-22 2009-12-10 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物和方法
CA2732686A CA2732686C (fr) 2008-12-22 2009-12-10 Compositions de modulateur de cellules sensorielles auriculaires a liberation controlee et procedes de traitement de troubles otiques
JP2011542272A JP6013736B2 (ja) 2008-12-22 2009-12-10 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US14003308P 2008-12-22 2008-12-22
US61/140,033 2008-12-22
US16023309P 2009-03-13 2009-03-13
US61/160,233 2009-03-13
US16481209P 2009-03-30 2009-03-30
US61/164,812 2009-03-30
GB0907070A GB2461962B (en) 2008-07-25 2009-04-24 Slow release NMDA receptor antagonist for otic disorders
GB0907070.7 2009-04-24
US17442109P 2009-04-30 2009-04-30
US61/174,421 2009-04-30
US12/504,553 US8496957B2 (en) 2008-07-21 2009-07-16 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US12/504,553 2009-07-16

Publications (2)

Publication Number Publication Date
WO2010074992A2 WO2010074992A2 (fr) 2010-07-01
WO2010074992A3 true WO2010074992A3 (fr) 2010-10-21

Family

ID=42288363

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/067552 WO2010074992A2 (fr) 2008-12-22 2009-12-10 Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques

Country Status (6)

Country Link
EP (1) EP2299976A4 (fr)
JP (4) JP6013736B2 (fr)
CN (2) CN102112111A (fr)
AU (1) AU2009330458B2 (fr)
CA (1) CA2732686C (fr)
WO (1) WO2010074992A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6170047B2 (ja) 2011-08-31 2017-07-26 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポトーシス−ターゲティングナノ粒子
ES2669561T3 (es) 2012-02-17 2018-05-28 University Of Georgia Research Foundation, Inc. Nanopartículas para el transporte mitocondrial de agentes
WO2015138992A1 (fr) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Administration de 3-bromopyruvate dans les mitochondries
CA2956324A1 (fr) * 2014-07-29 2016-02-04 Otonomy, Inc. Formulations otiques pour le traitement de ceruminose
EP3331547A4 (fr) 2015-08-05 2019-08-21 Children's Medical Center Corporation Compositions ayant des amplificateurs de perméation pour l'administration de médicaments
FI3458045T3 (fi) 2016-05-18 2024-10-24 Sound Pharmaceuticals Incorporated Ebselen käytettäväksi Ménièren taudin hoitoon
JP7277360B2 (ja) * 2016-09-14 2023-05-18 ザ チルドレンズ メディカル センター コーポレーション 薬物送達のための透過促進剤を有する組成物
US20190255080A1 (en) * 2016-09-16 2019-08-22 Viking Therapeutics, Inc. Method of reducing thyroid-associated side effects
BR112019010249A2 (pt) 2016-11-21 2019-09-10 Viking Therapeutics Inc método de tratamento de doença de armazenamento de glicogênio
WO2018112815A1 (fr) * 2016-12-22 2018-06-28 Nanjing University Modèle animal pour syndrome de perte auditive et sa méthode t de traitement
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
WO2019183004A1 (fr) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Formes cristallines et procédés de production de formes cristallines d'un composé
WO2020045162A1 (fr) * 2018-08-30 2020-03-05 学校法人慶應義塾 Support d'administration de médicament
JP2022510691A (ja) 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US20030092776A1 (en) * 1998-08-04 2003-05-15 Ron Eyal S. End modified thermal responsive hydrogels
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551626A1 (fr) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Gel thermoréversible utile comme excipient pharmaceutique pour une formation galénique
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US7589110B2 (en) * 2002-09-06 2009-09-15 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
WO2004022069A1 (fr) * 2002-09-06 2004-03-18 Durect Corporation Administration dans l'oreille interne de modulateurs de la neurotransmission glutamatergique
JP2005220070A (ja) * 2004-02-05 2005-08-18 Medgel Corp 神経再生および保護のための生体吸収性高分子ハイドロゲル製剤
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
JP2006111585A (ja) * 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
EP2932971A1 (fr) * 2005-03-04 2015-10-21 Otonomy, Inc. Formulations de la ketamine
SI1928405T1 (sl) * 2005-09-28 2014-12-31 Auris Medical Ag Farmacevtski sestavki za zdravljenje motenj notranjega ušesa
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
MX2010011545A (es) * 2008-04-21 2011-04-11 Otonomy Inc Formulaciones para tratar enfermedades y afecciones del oido.
RU2469726C2 (ru) * 2008-05-14 2012-12-20 Отономи, Инк. Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US20030092776A1 (en) * 1998-08-04 2003-05-15 Ron Eyal S. End modified thermal responsive hydrogels
US20040101560A1 (en) * 2002-11-27 2004-05-27 Sawchuk Ronald J. Methods and compositions for applying pharmacologic agents to the ear

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2299976A4 *

Also Published As

Publication number Publication date
WO2010074992A2 (fr) 2010-07-01
JP2012513394A (ja) 2012-06-14
JP6013736B2 (ja) 2016-10-25
JP2018138585A (ja) 2018-09-06
EP2299976A4 (fr) 2014-07-23
AU2009330458B2 (en) 2013-08-22
JP2015164943A (ja) 2015-09-17
CN102112111A (zh) 2011-06-29
CA2732686A1 (fr) 2010-07-01
JP6207093B2 (ja) 2017-10-04
JP2017160232A (ja) 2017-09-14
AU2009330458A1 (en) 2010-07-01
CN106344495A (zh) 2017-01-25
CA2732686C (fr) 2017-10-03
EP2299976A2 (fr) 2011-03-30

Similar Documents

Publication Publication Date Title
WO2010074992A3 (fr) Compositions de modulateur de cellules sensorielles auriculaires à libération contrôlée et procédés de traitement de troubles otiques
WO2010011609A3 (fr) Compositions antimicrobiennes à libération contrôlée et procédés pour le traitement de troubles otiques
WO2010008995A3 (fr) Compositions et procédés modulant l’apoptose à libération contrôlée pour le traitement de troubles otiques
WO2010011466A3 (fr) Compositions de modulation du snc à libération contrôlée et procédés de traitement des troubles otiques
WO2011050206A3 (fr) Compositions et procédés pour le traitement de troubles sino-nasaux
WO2011049958A3 (fr) Modulation de la température de gélification de formulations contenant des poloxamères
WO2010011605A3 (fr) Compositions à libération contrôlée modulant la structure otique et modulant le système immunitaire naturel et procédés de traitement de troubles otiques
WO2009132050A3 (fr) Préparations auriculaires de traitement de maladies et états otiques
WO2009139924A3 (fr) Compositions de corticostéroïdes à libération contrôlée et procédés pour le traitement de troubles otiques
EP4327888A3 (fr) Formulations orales d'analogues de cytidine et leurs procédés d'utilisation
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2012083017A3 (fr) Formes posologiques pour des médicaments médiocrement solubles administrés par voie orale à libération contrôlée et leurs utilisations
WO2010068281A3 (fr) Dispositif d’administration de médicament par lentille de contact
WO2010083239A3 (fr) Modulation thérapeutique de la lubrification limite de l'épithélium vaginal
MX2016002408A (es) Metodos para el tratamiento de trastornos oticos pediatricos.
WO2012027065A3 (fr) Polythérapie pour traiter des maladies
MX2018015635A (es) Composiciones y metodos para la modulacion de division de smn2 en un sujeto.
WO2008122049A3 (fr) Procédés et compositions pour la réduction des effets secondaires des traitements thérapeutiques
EA202091999A3 (ru) Применение ингибиторов dpp iv
WO2013063120A3 (fr) Modulateurs des récepteurs nmda et utilisations de ceux-ci
CO6311060A2 (es) Sistema intrauterino para suministrar una sustancia ó producto terapéutico directamente dentro del útero de un paciente y método para su fabricación
WO2010151755A3 (fr) Traitement de maladies inflammatoires à l'aide du microarn mir-124
WO2013052647A3 (fr) Formulations et utilisations d'agonistes sélectifs du récepteur de l'acide rétinoïque
WO2009038673A3 (fr) Modulateurs du récepteur d'histamine h4 de types thiéno- et furo-pyrimidine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980130562.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835529

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009835529

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009330458

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 637/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2011542272

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2732686

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009330458

Country of ref document: AU

Date of ref document: 20091210

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载